GlassScriptPhysician profile
Dana Vonette Wallace
NPI 1437192531
$43,963.57
in general payments reported to CMS, 2019-2025
31 companies · $7,945 in 2025
The $7,945 reported for 2025 was more than what 87% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,369 · 2020: $8,030 · 2021: $780 · 2022: $4,871 · 2023: $1,540 · 2024: $11K · 2025: $7,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $6,178 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,950 · Travel and Lodging: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,380.00 |
| Food and Beverage | $6,178.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,950.00 |
| Travel and Lodging | $1,405.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $11,192.18 | 2019-2025 | |
| Kaleo, INC. | $6,950.51 | 2019-2025 | Auvi-Q |
| Genentech USA, INC. | $6,377.60 | 2024 | Xolair |
| Alk-Abello, INC | $4,735.80 | 2019-2021 | |
| Abbvie INC. | $4,518.10 | 2022 | |
| Grifols USA, LLC | $3,378.87 | 2024 | Xembify |
| Genzyme Corporation | $1,190.77 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $842.49 | 2022-2025 | |
| Pharming Healthcare, INC. | $593.71 | 2023-2025 | Ruconest, Joenja |
| Blueprint Medicines Corporation | $591.53 | 2023-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $494.94 | 2021-2024 | Orladeyo |
| Csl Behring | $360.23 | 2023-2025 | Haegarda, Andembry, Hizentra |
| Astrazeneca Pharmaceuticals LP | $292.50 | 2021-2023 | Tezspire |
| Glaxosmithkline, LLC. | $248.05 | 2022-2023 | |
| Aquestive Therapeutics, INC. | $222.59 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eagle Pharmaceuticals, INC. | $200.00 | 2019 | |
| Genentech, INC. | $182.03 | 2023-2024 | Xolair |
| Harrow Eye, LLC | $161.42 | 2025 | Vevye |
| Adma Biomanufacturing LLC | $151.30 | 2024 | |
| Galderma Laboratories, L.P. | $150.00 | 2025 | Nemluvio |
| Leo Pharma As | $145.00 | 2019 | |
| X4 Pharmaceuticals, INC. | $135.00 | 2024 | Xolremdi |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2021 | |
| Ionis Pharmaceuticals, INC. | $121.98 | 2025 | Dawnzera |
| Sanofi US Services INC. | $119.81 | 2025 | |
| Amgen INC. | $117.93 | 2023 | Tezspire |
| Merz North America, INC. | $103.60 | 2019 | |
| Grifols Shared Services North America, INC. | $94.43 | 2024 | Xembify |
| Teva Pharmaceuticals USA, INC. | $61.04 | 2019 | |
| Kyowa Kirin, INC. | $60.37 | 2025 | |
| Allergan, INC. | $44.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.